Cytoplasmic Trop-1/Ep-CAM Overexpression is Associated with a Favorable Outcome in Node-positive Breast Cancer
Authors:
- Saverio AlbertiSASaverio Alberti
- Federico AmbrogiFAFederico Ambrogi
- Patrizia BoracchiPBPatrizia Boracchi
- Marco ForniliMFMarco Fornili
- Patrizia QuerzoliPQPatrizia Querzoli
- Massimo PedrialiMPMassimo Pedriali
- Rossano LattanzioRossano Lattanzio
- Mauro PiantelliMPMauro Piantelli
- Elia BiganzoliEBElia Biganzoli
- Danila CoradiniDCDanila Coradini
Open Access
- 16 October 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 42 (12) , 1128-1137
Abstract
Trop-1/Ep-CAM modulates growth and survival of transformed cells, and it is highly expressed in most carcinomas including breast cancer. Only membranous staining is typically considered in evaluating Trop-1/epithelial cell adhesion molecule (Ep-CAM) expression in tumor cells. However, there is evidence of retention of Trop-1/Ep-CAM, as functionally incompetent molecules, in intra-cytoplasmic vesicles. Hence, we investigated whether cytoplasmic immunostaining may have an independent clinical significance with respect to membranous staining. Membranous and cytoplasmic Trop-1/Ep-CAM expression was immunohistochemically investigated in 642 unilateral breast cancers from patients with a 99-month median follow-up. Multiple correspondence analysis was used to investigate the association between Trop-1/Ep-CAM and other biological variables. The impact of Trop-1/Ep-CAM expression on the patient's outcome was evaluated as event-free survival by the Kaplan–Meier method and proportional hazard Cox model. While tumors with intermediate/strong membranous staining were mostly associated with concomitant cytoplasmic Trop-1/Ep-CAM expression (97%), tumors with weak-to-nil membranous staining showed intermediate/high cytoplasmic expression in 23% of cases. Cytoplasmic overexpression was associated with a favorable outcome, especially in node-positive patients, regardless of the adjuvant therapy received. Trop-1/Ep-CAM expression may have different clinical implications according to its subcellular localization.Keywords
This publication has 35 references indexed in Scilit:
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerAnnals of Oncology, 2010
- Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical studyLaboratory Investigation, 2009
- Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in CarcinomaCell, 2008
- Cancer stem cells in solid tumours: accumulating evidence and unresolved questionsNature Reviews Cancer, 2008
- Trop‐1 are conserved growth stimulatory molecules that mark early stages of tumor progressionCancer, 2007
- aPKCζ cortical loading is associated with Lgl cytoplasmic release and tumor growth in Drosophila and human epitheliaOncogene, 2007
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003
- Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAMGene Therapy, 1999
- Biochemical and immunological characterization of the human carcinoma‐associated antigen MH 99/KS 1/4International Journal of Cancer, 1993
- Partial residuals for the proportional hazards regression modelBiometrika, 1982